Research Topics
| C R LinesSummaryAffiliation: Merck Research Laboratories Country: USA Publications
| Collaborators
|
Detail Information
Publications
A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patientsC R Lines
Merck and Co, Inc, P O Box 4, West Point, PA 19486, USA
Pain 93:185-90. 2001..Use of the VAS imposed additional administrative burdens. These findings suggest that the 4GS may be the preferred scale for assessing headache pain in clinical trials involving adult migraineurs...- Rizatriptan: pharmacological differences from sumatriptan and clinical resultsC R Lines
Merck Research Laboratories, West Point, PA, USA
Curr Med Res Opin 17:s54-8. 2001..The most common side-effects on both drugs occurred in <10% of patients and consisted of dizziness, drowsiness, and asthenia/fatigue. The adverse events were usually mild or moderate in severity and short-lasting... - Telephone screening for amnestic mild cognitive impairmentChristopher R Lines
Merck Research Laboratories, West Point, PA, USA
Neurology 60:261-6. 2003.... - Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probeAnup K Majumdar
Merck Research Laboratories, West Point, PA 19422, USA
Clin Pharmacol Ther 74:150-6. 2003..The effect of aprepitant on in vivo CYP3A4 activity in humans with oral midazolam used as a sensitive probe of CYP3A4 activity was evaluated in this study... 
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adultsT W Ho
Merck Research Laboratories, North Wales, PA 19454 1099, USA
Cephalalgia 29:711-8. 2009..Age appeared to be an important predictor of placebo response rate in rizatriptan trials, with older patients being less likely to respond to placebo and more likely to respond to rizatriptan...- Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trialJ J Sevigny
Merck Research Laboratories, North Wales, PA 19454, USA
Neurology 71:1702-8. 2008..We examined whether the growth hormone secretagogue MK-677 (ibutamoren mesylate), a potent inducer of IGF-1 secretion, slows the rate of progression of symptoms in patients with AD... - Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraineT W Ho
Merck Research Laboratories, UG 4C 18, PO Box 1000, North Wales, PA 19454 1099, USA
Neurology 70:1304-12. 2008..To determine an effective and tolerable dose of a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, MK-0974, for the acute treatment of migraine... - Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled studyS A Reines
Merck Research Laboratories, 10 Sentry Parkway, Blue Bell, PA 19422, USA
Neurology 62:66-71. 2004.... - Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisoloneJacqueline B McCrea
Merck Research Laboratories, Bluebell, PA 19422, USA
Clin Pharmacol Ther 74:17-24. 2003..These findings suggest that the dose of these corticosteroids should be adjusted when given with aprepitant... - A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairmentLeon J Thal
University of California, San Diego, CA, USA
Neuropsychopharmacology 30:1204-15. 2005..In conjunction with the lack of effects observed in previous AD studies, the findings suggest that inhibition of COX-2 is not a useful therapeutic approach in AD... - Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trialPaul S Aisen
Georgetown University Medical Center, Washington, DC, USA
Curr Alzheimer Res 5:73-82. 2008..The significance of the observation that rofecoxib increased the rate of conversion from MCI to AD remains uncertain...